A Phase I Safety Study of Allogeneic Bone Marrow Derived MSCs for Refractory Perianal Fistulizing Crohn's Disease
Latest Information Update: 26 Dec 2022
At a glance
- Drugs OSSM-001 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Sponsors Ossium Health
Most Recent Events
- 21 Dec 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 02 Jun 2022 Status changed from planning to not yet recruiting.
- 18 Mar 2022 New trial record